Bayer Aktiengesellschaft (BAYRY)

OTCMKTS · Delayed Price · Currency is USD
13.74
+0.68 (5.21%)
Jun 30, 2026, 2:57 PM EST
Market Cap51.65B +67.9%
Revenue (ttm)52.16B -2.9%
Net Income-2.49B
EPS-2.53
Shares Out n/a
PE Ration/a
Forward PE10.31
Dividend0.02 (0.17%)
Ex-Dividend DateApr 28, 2026
Volume224,691
Open13.60
Previous Close13.06
Day's Range13.42 - 13.75
52-Week Range7.19 - 14.85
Beta0.85
AnalystsBuy
Price Target14.19 (+3.28%)
Earnings DateAug 4, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]

Sector Healthcare
Founded 1863
Employees 87,757
Stock Exchange OTCMKTS
Ticker Symbol BAYRY
Full Company Profile

Financial Performance

In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.

Financial numbers in EUR Financial Statements

Analyst Summary

According to 4 analysts, the average rating for BAYRY stock is "Buy." The 12-month stock price target is $14.19, which is an increase of 3.28% from the latest price.

Price Target
$14.19
(3.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bayer Gets New Life After Supreme Court's Roundup Ruling

A high-court victory gives the German company more leverage to settle outstanding cases.

4 days ago - WSJ

Bayer says Durnell Roundup ruling ‘should help significantly contain litigation’

Bayer (BAYRY) stated: “The U.S. Supreme Court issued a 7:2 landmark ruling in the Durnell Roundup case on Thursday, affirming that the Federal Insecticide, Fungicide, and Rodenticide Act expressly pre...

5 days ago - TheFly

Bayer's stock jumps after Supreme Court sides with Roundup weedkiller manufacturer

The court ruled that states cannot have differing labeling warning rules than federal law requires.

5 days ago - Market Watch

Bayer wins Supreme Court case making it harder to sue over glyphosate in Monsanto's Roundup

The Supreme Court in a 7-2 decision on Thursday said Bayer cannot be sued over state-level claims that the company failed to warn of cancer risks from its weedkiller Roundup and its chemical glyphosat...

5 days ago - CNBC

Bayer Not Liable After Man Claimed Weedkiller Caused His Cancer, Supreme Court Rules

The Supreme Court ruled in favor of former agrochemical giant Monsanto on Thursday in a dispute over whether the company should have warned consumers about potential harms arising from its weed killer...

5 days ago - Forbes

Bayer shares surge after U.S. Supreme Court rules in favour of company

Shares in Germany's Bayer surged ​by the most ‌in 23 years on Thursday after the ​U.S. Supreme Court ​sided with the the ⁠company concerning lawsuits ​related its Roundup weedkiller.

5 days ago - Reuters

Bayer confirms Supreme Court rules in favor of Monsanto in Durnell case

Bayer (BAYRY) issued the following statement: “The U.S. Supreme Court decision is good for science, farmers, and industries that depend on regulatory clarity for innovation. It should help significant...

5 days ago - TheFly

Bayer Wins Supreme Court Challenge Over Roundup Litigation

The decision will help the company in its bid to resolve thousands of claims that the popular weedkiller caused cancer.

5 days ago - WSJ

Bayer, Iambic collaborate for AI drug discovery

Bayer (BAYRY) and Iambic Therapeutics announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic’s AI-driven platform. The collaboration is focused on small molec...

8 days ago - TheFly

Bayer and Iambic Collaborate to Advance Drug Discovery with AI

BERLIN & SAN DIEGO--(BUSINESS WIRE)--Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a...

8 days ago - Business Wire

Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada

CALGARY, Alberta--(BUSINESS WIRE)--The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this ro...

11 days ago - Business Wire

Judge sends Roundup class settlement back to Missouri court, Bloomberg says

A federal judge has remanded the Roundup settlement back to the Missouri State Court, according to Bloomberg’s Alexey Anishchuk, citing an emailed statement from Bayer (BAYRY). Bayer’s U.S. subsidiary...

13 days ago - TheFly

Federal judge sends Bayer's $7.25 billion Roundup settlement back to Missouri state court

A federal judge on ‌Wednesday returned Bayer's proposed $7.25 billion settlement of Roundup lawsuits to Missouri state court, overruling the ​objections of some cancer victims who ​said the state cour...

13 days ago - Reuters

Bayer Completes Acquisition of Perfuse Therapeutics

BERLIN--(BUSINESS WIRE)--Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced p...

13 days ago - Business Wire

Bayer price target raised to EUR 40.50 from EUR 40 at Berenberg

Berenberg analyst Sebastian Bray raised the firm’s price target on Bayer (BAYRY) to EUR 40.50 from EUR 40 and keeps a Hold rating on the shares.

15 days ago - TheFly

Bayer announces FDA approval for Ambelvist

Bayer (BAYRY) announced that the FDA approved Ambelvist, a new, intravenous macrocyclic gadolinium-based contrast agent indicated for contrast-enhanced magnetic resonance imaging to detect and visuali...

15 days ago - TheFly

Bayer's AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contras...

15 days ago - Business Wire

Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch

Bayer is hoping to speed up a plan to facilitate North American production of biofuel feedstocks like camelina in the wake of the Iran ​war, the drug-making and crop science giant said on Wednesday.

20 days ago - Reuters

Bayer appoints Reinhard as President of the Radiology business

Bayer (BAYRY) announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will re...

21 days ago - TheFly

Dr. Jost Reinhard Appointed President of Bayer's Radiology Business

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer's Pharmaceuticals Division, effective August 1, 2026. ...

21 days ago - Business Wire

Bayer announces leadership changes within Consumer Health division

Bayer (BAYRY) announced leadership changes within its Consumer Health division. Key leadership appointments include: Samantha Avivi appointed global Chief Marketing Officer, Consumer Health; Analia de...

22 days ago - TheFly

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further en...

22 days ago - Business Wire

Bayer says Kerendia met primary endpoint in Phase III FIND-CKD trial

Bayer (BAYRY) announced full results from the Phase III FIND-CKD trial investigating Kerendia in adults with non-diabetic chronic kidney disease who were also receiving background standard of care. In...

25 days ago - TheFly

Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney dise...

25 days ago - Business Wire

Bayer says no plans to restructure despite litigation threat

Bayer has no plans to spin off Monsanto, a representative said on Tuesday, ‌even as the company faces an avalanche of lawsuits over its Roundup weedkiller.

27 days ago - Reuters